IXICO selected by new large global pharma for orphan drug clinical trial

IXICO plc, the AI data analytics company delivering insights in neuroscience, has secured a contract for neuroimaging solutions with a new, large global pharmaceutical company. The Phase IIB trial will investigate an orphan drug designated clinical asset for the treatment of Huntington's disease.

Huntington's disease (HD) is a progressive and devastating neurodegenerative disorder for which no disease-modifying therapies currently exist. Orphan drug designations help biopharmaceutical sponsors undertake valuable investigations and develop treatments for rare and complex conditions such as HD. Since its inception in 2004, IXICO has had an extensive track record of delivering innovative neuroimaging solutions to support clients in optimising their pipelines for rare diseases.

Lammert Albers, Chief Commercial Officer of IXICO, commented: "We are delighted to be chosen to take part in this HD study to advance development of promising medical treatments for this devastating rare disease. This contract and new partnership will further endorse our breakthrough neuroimaging technologies with large pharma sponsors across the full spectrum of the drug development pathway."

 

For further information please contact:

IXICO plc

+44 (0)20 3763 7498

Giulio Cerroni, Chief Executive Officer

Grant Nash, Chief Financial Officer

 

 

 

Walbrook PR Ltd

    +44 (0)20 7933 8780

Paul McManus / Lianne Cawthorne /

IXICO@walbrookpr.com

Alice Woodings

 

         

Date: 08/12/2020